{Reference Type}: Case Reports
{Title}: Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series.
{Author}: He X;Yang D;Lai L;Lang J;Wei K;Xiao M;
{Journal}: Clin Cosmet Investig Dermatol
{Volume}: 17
{Issue}: 0
{Year}: 2024
{Factor}: 2.765
{DOI}: 10.2147/CCID.S458592
{Abstract}: Alopecia Areata is a hair disorder influenced by factors such as genetics, immune system, and environmental triggers. The pathogenesis of this condition is still unclear, leading to unsatisfactory current treatments and causing a large number of patients to suffer from it. Janus kinase inhibitors are a new class of drugs that have emerged in recent years and are expected to be promising therapeutic tools for alopecia areata. We report five patients with varying backgrounds and severity of alopecia areata. All of them had received conventional therapy without success. Five patients took Upadacitinib at a dose of 15 mg once daily, and all of them achieved satisfactory efficacy. No adverse events were observed during the treatment of 5 patients.